NCT06604715View on ClinicalTrials.gov

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

November 3, 2027

Study Completion Date

November 30, 2028

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

JNJ-87562761

JNJ-87562761 will be administered.

Trial Locations (14)

404

RECRUITING

China Medical University Hospital, Taichung

833

RECRUITING

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

10002

RECRUITING

National Taiwan University Hospital, Taipei

28040

RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

31008

RECRUITING

Clinica Univ. de Navarra, Pamplona

57007

RECRUITING

Hosp Clinico Univ de Salamanca, Salamanca

70403

RECRUITING

National Cheng Kung University Hospital, Tainan City

M5G 2M9

RECRUITING

Princess Margaret Hospital, Toronto

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

137 701

RECRUITING

The Catholic University of Korea Seoul St Marys Hospital, Seoul

08916

RECRUITING

Hosp. Univ. Germans Trias I Pujol, Badalona

08036

RECRUITING

Hosp Clinic de Barcelona, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY